The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.

Han Solo ignores C-3PO's advice. Stakeholders involved with predictive AI must ramp up on a semi-technical understanding that comes down to 1) what's predicted, 2) how well and 3) what's done about it ...